We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.50 | 0.64% | 1,646.50 | 1,646.00 | 1,646.50 | 1,656.00 | 1,635.00 | 1,642.00 | 1,921,503 | 14:07:38 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.78 | 67.89B |
From Apr 2019 to Apr 2024
TIDMGSK
RNS Number : 9488U
GlaxoSmithKline PLC
17 July 2018
GlaxoSmithKline plc (the 'Company')
Transaction notification
Hot Features
Premium
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Ms E Walmsley
=== ======================== =============================================
b) Position/status Chief Executive Officer
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 189
----------
GBP15.766 206
----------
GBP15.766 721
----------
GBP15.766 189
----------
GBP15.766 206
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
1511
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr R G Connor
=== ======================== =============================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 128
----------
GBP15.766 107
----------
GBP15.766 152
----------
GBP15.766 107
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
494
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr L Debruyne
=== ======================== =============================================
b) Position/status President, Global Vaccines
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 180
----------
GBP15.766 228
----------
GBP15.766 180
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
588
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr S Dingemans
=== ======================== =============================================
b) Position/status Chief Financial Officer
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 249
----------
GBP15.766 187
----------
GBP15.766 510
----------
GBP15.766 249
----------
GBP15.766 187
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
1382
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr N Hirons
=== ======================== =============================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 92
----------
GBP15.766 67
----------
GBP15.766 80
----------
GBP15.766 92
----------
GBP15.766 67
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
398
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr B McNamara
==== ========================= ===============================================
b) Position/status CEO, GSK Consumer Healthcare
==== ========================= ===============================================
c) Initial notification/ Initial notification
amendment
==== ========================= ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================
a) Name GlaxoSmithKline plc
==== ========================= ===============================================
b) LEI 5493000HZTVUYLO1D793
==== ========================= ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ========================= ===============================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 12
July 2018 on ADSs held in the Company's
Deferred Annual Bonus Plan.
==== ========================= ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$41.75 78
----------
$41.75 76
----------
==== ========================= ===============================================
d) Aggregated information
Aggregated volume
Price
154
$41.75
============================== ===============================================
e) Date of the transaction 2018-07-12
==== ========================= ===============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ========================= ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr L Miels
=== ======================== =============================================
b) Position/status President, Global Pharmaceuticals
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 145
----------
=== ======================== =============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr D S Redfern
=== ======================== =============================================
b) Position/status Chief Strategy Officer
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 117
----------
GBP15.766 85
----------
GBP15.766 148
----------
GBP15.766 117
----------
GBP15.766 85
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
552
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Ms K Terrell
=== ======================== ===============================================
b) Position/status Chief Digital & Technology Officer
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ===============================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 12
July 2018 on ADSs held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$41.75 25
----------
=== ======================== ===============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===============================================
e) Date of the transaction 2018-07-12
=== ======================== ===============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Ms C Thomas
=== ======================== =============================================
b) Position/status SVP, Human Resources
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 172
----------
GBP15.766 128
----------
GBP15.766 161
----------
GBP15.766 172
----------
GBP15.766 128
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
761
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr P C Thomson
=== ======================== =============================================
b) Position/status President, Global Affairs
=== ======================== =============================================
c) Initial notification/ Initial notification
amendment
=== ======================== =============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ======================== =============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== =============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== =============================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 12 July 2018 on Ordinary
Shares held in the Company's Deferred Annual
Bonus Plan.
=== ======================== =============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.766 105
----------
GBP15.766 80
----------
GBP15.766 100
----------
=== ======================== =============================================
d) Aggregated information
Aggregated volume
Price
285
GBP15.766
=== ======================== =============================================
e) Date of the transaction 2018-07-12
=== ======================== =============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== =============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr D E Troy
==== ========================= ===============================================
b) Position/status SVP & General Counsel
==== ========================= ===============================================
c) Initial notification/ Initial notification
amendment
==== ========================= ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================
a) Name GlaxoSmithKline plc
==== ========================= ===============================================
b) LEI 5493000HZTVUYLO1D793
==== ========================= ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ========================= ===============================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 12
July 2018 on ADSs held in the Company's
Deferred Annual Bonus Plan.
==== ========================= ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$41.75 100
----------
$41.75 82
----------
$41.75 89
----------
$41.75 100
----------
$41.75 82
----------
==== ========================= ===============================================
d) Aggregated information
Aggregated volume
Price
453
$41.75
============================== ===============================================
e) Date of the transaction 2018-07-12
==== ========================= ===============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ========================= ===============================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHQDLFFVDFZBBL
(END) Dow Jones Newswires
July 17, 2018 12:46 ET (16:46 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
